Thymectacin: Difference between revisions – Wikipedia

From Wikipedia, the free encyclopedia

Content deleted Content added


 

Line 6: Line 6:

| IUPAC_name = (2”S”)-methyl 2-((((2”R”,3”S”,5”R”)-5-(5-((”E”)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

| IUPAC_name = (2”S”)-methyl 2-((((2”R”,3”S”,5”R”)-5-(5-((”E”)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

| image = Thymectacin.svg

| image = Thymectacin.svg

| image_class = skin-invert-image

| alt = Skeletal formula of thymectacin

| alt = Skeletal formula of thymectacin

| width = 260

| width = 260

| image2 = Thymectacin-3D-spacefill.png

| image2 = Thymectacin-3D-spacefill.png

| image_class2 = bg-transparent

| alt2 = Space-filling model of the thymectacin molecule

| alt2 = Space-filling model of the thymectacin molecule

| width2 = 240

| width2 = 240


Latest revision as of 17:07, 10 January 2026

Chemical compound

Pharmaceutical compound

Thymectacin
Skeletal formula of thymectacin
Space-filling model of the thymectacin molecule
Other names NB-1011; NB-101; N-[[5-[(E)-2-Bromovinyl]-2′-deoxyuridin-5′-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester
  • (2S)-methyl 2-((((2R,3S,5R)-5-(5-((E)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Formula C21H25BrN3O9P
Molar mass 574.321 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)OC)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)n2cc(c(=O)[nH]c2=O)/C=C/Br)O)Oc3ccccc3

  • InChI=1S/C21H25BrN3O9P/c1-13(20(28)31-2)24-35(30,34-15-6-4-3-5-7-15)32-12-17-16(26)10-18(33-17)25-11-14(8-9-22)19(27)23-21(25)29/h3-9,11,13,16-18,26H,10,12H2,1-2H3,(H,24,30)(H,23,27,29)/b9-8+/t13-,16-,17+,18+,35?/m0/s1 ☒N
  • Key:CFBLUORPOFELCE-BACVZHSASA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Thymectacin (NB-1011, NB-101) is an experimental anticancer prodrug of brivudine monophosphate. It is being developed by New Biotics and it entered in phase I clinical trials for colon cancer in 2006.[1]

Thymectacin is a small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVdU) with potential antineoplastic activity.[2] It is selectively active against tumor cells expressing high levels of thymidylate synthase (TS). Thymectacin is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top